Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC

This publication has 21 references indexed in Scilit:

• Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis
  European Journal of Surgical Oncology, 2017
• Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors
  Annals of Surgical Oncology, 2016
• The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery
  Journal of Surgical Oncology, 2014
• The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study
  Journal of Surgical Oncology, 2013
• Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
  Journal of Clinical Oncology, 2009
• Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy
  Journal of Surgical Oncology, 2008
• Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis
  Annals of Surgical Oncology, 2007
• Peritoneal Carcinomatosis of Colorectal Origin
  Annals of Surgery, 2006
• Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin
  Annals of Surgical Oncology, 2004
• Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
  Journal of Clinical Oncology, 2003